Tackling "Undruggable" Targets
RAtionally Developed Cell-Penetrating Peptide Therapeutics to RADically Enhance Patient Therapy
About RAD Therapeutics
Mission
Strategy
Strategy
RAtionally Develop Cell-Penetrating Peptide Therapeutics
against challenging targets, to RADically improve treatment of serious diseases
Strategy
Strategy
Strategy
Harness the high selectivity and low toxicity of peptides, discover and engineer cell-penetrating, stable and optimized peptides, to create transformational proprietary therapeutics against validated intracellular targets that are considered "undruggable"
Path
Strategy
Path
Our 1st Drug Candidate is a potential breakthrough cancer therapy:
Novel “decoy” peptide directly inhibits a 'holy-grail' 'undruggable' pan-cancer oncogene and its protein-protein-interactions (PPIs).
Alters essential cancer hallmarks Suppresses tumor growth and Promotes immune-response
We have established pre-clinical POC with our lea
Our 1st Drug Candidate is a potential breakthrough cancer therapy:
Novel “decoy” peptide directly inhibits a 'holy-grail' 'undruggable' pan-cancer oncogene and its protein-protein-interactions (PPIs).
Alters essential cancer hallmarks Suppresses tumor growth and Promotes immune-response
We have established pre-clinical POC with our lead peptide against Lung Cancer, showing over 90% Tumor Growth Inhibition
RAD therapies
Lead Target - SURVIVIN/BIRC5
SURVIVIN is a ‘holy-grail’ ‘undruggable’ intracellular oncogene. SURVIVIN is prominently expressed during embryonal development and is absent in most terminally differentiated normal cells. It is, however, highly overexpressed in a variety of human cancers, including lung adenocarcinoma, and is a validated prognostic marker.
Its expression has been correlated with increased tumor resistance to a broad range of chemotherapy agents, radiation insensitivity and poor patient prognosis.
Lung Cancer - Lead Indication with high unmet need
Over 240,000 new lung cancer patients in the US every year
5-year survival of lung cancer patients is still unacceptably low at app. 27%
Approximately 67,000 of these new lung cancer patients suffer from NSCLC Adenocarcinoma with elevated expression of SURVIVIN.
These 67,000 patients each year could RADically benefit from our targeted therapy
https://seer.cancer.gov/statfacts/html/lungb.html?utm_source=chatgpt.com
Drug Discovery - RAD-001
We identified the SURVIVIN-derived peptide segment which is key to its dimerization, and essential for its activity and its protein protein interactions (PPIs). We engineered a cell penetrating nucleus-directed "decoy peptide" optimized for plasma stability to directly and selectivity inhibit SURVIVIN and its PPIs.
Proof of Concept - RAD-001
Administering our drug in lung cancer models resulted in profound effects on tumor hallmarks without impacting normal tissue: Over 90% Tumor Growth Inhibition without toxicity, inducing tumor cell-death, transforming residual tumor cells to ‘normal-like’ cells, and promoting tumor infiltration of CD8+ T-cells - turning ‘cold’ tumors to ‘hot’’.
Precision Medicine
Our approach leverages use of SURVIIVIN expression as a biomarker to direct our treatment to the patients who are most likely to benefit.
•Highly selective modality with pan-cancer potential and no observed toxicity nor anticipated off target effects
Potential Application
Highly promising as anti-cancer monotherapy against multiple solid and hematological cancers that express SURVIVIN (biomarker)
Potential for synergy in combination with Immune-therapy and with chemo/radiation therapy
Highly selective with no notable toxicity
Biomanufacturing
State-of-the-art synthetic manufacturing assures cost-effective manufacturing of high and consistent product quality
Revolutionizing Medicine
Team
Prof. Varda Shoshan-Barmatz(Ph.D), Co-Founder, Inventor and Lead Scientist
Professor at the Department of Life-Sciences at Ben-Gurion University (BGU) in Israel and a renowned scientist and leading expert in the field of mitochondrial biology and cancer research. Prof. Shoshan-Barmatz has held various leadership positions, including as Director of Israel’s National Institute of Biotechnology in the Negev (NIBN) and is a prolific researcher and innovator.
Gilead Raday (MSc., M.Phil), Co-Founder
Biopharma executive with a track record in developing new drugs all the way to FDA approval. An insightful and experienced integrator of scientific innovation, R&D operations, clinical & regulatory strategy, with commercial, financial and corporate development.
Prof. Nir Peled (MD, Ph.D), Medical Advisor
Head of the Oncology Division at Shaare-Zedek Medical Center at the Hebrew University, Jerusalem, Israel. A KOL in the field of thoracic oncology, including personalized targeted therapy, immunotherapy, cancer evolution, biomarker development, and early detection. Prof. Peled was a board member at the International Association of Lung Cancer (IASLC) and the past-chair of its Screening & Early Detection committee, as well as the previous Chair of the Thoracic Cancer Assembly of the European Thoracic Society. Currently he is the head of the Global Multidisciplinary Practice Standards of the IASLC.
Key Publications
1.Santhanam M, Kumar Pandey S, Shteinfer-Kuzmine A, Paul A, Abusiam N, Zalk R, Shoshan-Barmatz V. Interaction of SMAC with a survivin-derived peptide alters essential cancer hallmarks: Tumor growth, inflammation, and immunosuppression. Mol Ther. 2024 Jun 5;32(6):1934-1955. doi: 10.1016/j.ymthe.2024.04.007. Epub 2024 Apr 5. PMID: 38582961; PMCID: PMC11184343.
2.Wang, Q.; Greene, M.I., Survivin as a Therapeutic Target for the Treatment of Human Cancer. Cancers (2024), 16, 1705. https://doi.org/10.3390/cancers16091705
Tackling "Undruggable" Targets in Serious Diseases
At RAD Therapeutics, our mission is to RADically improve the lives of patients through RAtional Development of innovative cell-penetrating peptide therapeutics.